TerminatedNot Applicable

Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Stopped: Subjects did not receive Hope Pharmaceuticals' Sodium Thiosulfate Injection.

United States5 participantsStarted 2017-10-20

Plain-language summary

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previously enrolled as a patient in ST-001 CALISTA study * Willing to provide written informed consent * Willing and able to adhere to all study-related procedures * Willing to authorize release of medical records * Willing to authorize collection of medical data from health care providers * Provide email, home address and phone number where he/she can be reached Exclusion Criteria: • Patient did not participate in ST-001 CALISTA study

What they're measuring

Observation of delayed adverse events, standard of care treatments for calciphylaxis following participation in ST-001

Timeframe: 8 weeks

Trial details

NCT IDNCT03319914

SponsorHope Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-11-09

View on ClinicalTrials.gov More Calciphylaxis trials